Literature DB >> 10326690

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

M Chiaramonte1, T Stroffolini, A Vian, M A Stazi, A Floreani, U Lorenzoni, S Lobello, F Farinati, R Naccarato.   

Abstract

BACKGROUND: Cirrhosis of viral etiology due to hepatitis B virus (HBV) or hepatitis C virus (HCV) infection is a risk factor for hepatocellular carcinoma (HCC). The current study evaluated the rate of incidence of HCC in patients with compensated cirrhosis of viral etiology.
METHODS: Two hundred fifty-nine cirrhotic patients (66 hepatitis B surface antigen [HBsAg] positive, 166 HCV positive, and 27 HBsAg/HCV positive) were longitudinally examined every 6 months by serum alpha-fetoprotein test and liver ultrasonography. The rates of incidence of HCC were calculated by the person-years method. The Kaplan-Meier method was used to estimate the cumulative probability of HCC development. Differences in survival time were evaluated by a log rank test. Independent predictors of HCC development were estimated by Cox proportional hazard regression analysis.
RESULTS: During a mean follow-up of 64.5 months, HCC developed in 51 (19.7%) patients: in 34 of 166 HCV positive subjects (20.5%) (mean follow-up, 66.3 months), in 6 of 66 of those HBsAg positive (9.1%) (mean follow-up, 55.06 months), and in 11 of 27 of those with dual HBsAg/HCV infection (40.7%) (mean follow-up, 76.4 months). The rate of incidence of HCC per 100 person-years of follow-up was 3.7 in HCV positive subjects, 2.0 in those HBsAg positive, and 6.4 in those with dual infection. Cumulative HCC appearance rates in HBsAg positive, HCV positive, and HBsAg/HCV positive subgroups were 10%, 21%, and 23% at 5 years, 16%, 28%, and 45% at 10 years, and 16%, 40%, and 55% at 13 years, respectively. Multivariate analysis indicated that age >50 years (hazard risk [HR], 4.5; 95% confidence interval [CI] = 2.1-9.4), male gender (HR, 2.8; 95% CI = 1.1-5.3), and HBsAg/HCV coinfection (HR, 2.3; 95% CI = 1.1-4.6) were independent predictors of HCC development.
CONCLUSIONS: These findings confirm that male gender and more advanced age (>50 years) are risk factors for HCC in patients with cirrhosis. Furthermore, the data indicate that subjects with dual HBsAg/HCV infection are at highest risk for HCC. Surveillance programs for early detection of HCC should focus especially on these patients.

Entities:  

Mesh:

Year:  1999        PMID: 10326690

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  57 in total

1.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection.

Authors:  Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Chien-Hung Chen; Kuo-Chin Chang; Yi-Hao Yen; Yuan-Hung Kuo; Ming-Chao Tsai; Sheng-Nan Lu; Chuan-Mo Lee
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

3.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

4.  Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series.

Authors:  Robert J Wong; Robert Gish; Todd Frederick; Natalie Bzowej; Catherine Frenette
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

Review 5.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

6.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 7.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

8.  Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies.

Authors:  Robert D Mair; Antonia Valenzuela; Nghiem B Ha; Walid S Ayoub; Tami Daugherty; Glen A Lutchman; Gabriel Garcia; Aijaz Ahmed; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

9.  Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.

Authors:  David W Hutton; Samuel K So; Margaret L Brandeau
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

10.  Serological and molecular expression of Hepatitis B infection in patients with chronic Hepatitis C from Tunisia, North Africa.

Authors:  Samar Ben Halima; Olfa Bahri; Nadia Maamouri; Imed Cheikh; Nissaf Ben Alaya; Amel Sadraoui; Ons Azaiez; Msaddak Azouz; Nabyl Ben Mami; Henda Triki
Journal:  Virol J       Date:  2010-09-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.